secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-01-24T23:59:59+00:00
Accession:  0001599298-25-000038
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics discloses ~$412M cash balance, awards $540K bonuses to CEO/CFO
--------------------------------------------------------------------------------

- Preliminary unaudited cash, equivalents, and short-term investments ~$412M as of Dec 31, 2024, including $31.8M loan repayment.
- CEO Dr. Zanganeh and CFO Manmeet Soni each granted $540K cash bonus for FY2024, payable Q1 2025; no bonus in FY2023.
- Base salaries for both officers increase from $600K to $618K, effective February 1, 2025.
- Cash balance is preliminary and subject to year-end closing adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000038/0001599298-25-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000038/smmt-20250122.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer